Gilead Sciences (NASDAQ:GILD) Given a $82.00 Price Target by BMO Capital Markets Analysts

BMO Capital Markets set a $82.00 price objective on Gilead Sciences (NASDAQ:GILD) in a research report sent to investors on Wednesday morning, TipRanks reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently commented on GILD. Wells Fargo & Co raised shares of Gilead Sciences from a market perform rating to an outperform rating and raised their target price for the company from $68.00 to $88.00 in a research note on Monday, July 15th. Morgan Stanley set a $82.00 target price on shares of Gilead Sciences and gave the company a hold rating in a research note on Monday, July 15th. Jefferies Financial Group set a $95.00 target price on shares of Gilead Sciences and gave the company a buy rating in a research note on Monday, July 15th. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the company a buy rating in a research note on Monday, July 15th. Finally, ValuEngine raised shares of Gilead Sciences from a sell rating to a hold rating in a research note on Thursday. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences currently has an average rating of Buy and an average price target of $82.29.

Shares of GILD stock traded down $0.52 during mid-day trading on Wednesday, reaching $64.95. The company’s stock had a trading volume of 5,837,640 shares, compared to its average volume of 6,935,655. The firm’s 50 day moving average is $67.26. Gilead Sciences has a 12-month low of $60.32 and a 12-month high of $79.61. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53. The stock has a market cap of $85.53 billion, a price-to-earnings ratio of 10.56, a PEG ratio of 4.06 and a beta of 1.12.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.54 billion. During the same quarter last year, the firm posted $1.91 EPS. The business’s revenue for the quarter was down 2.8% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences will post 6.62 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.88%. The ex-dividend date is Thursday, September 12th. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.

In other news, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total value of $399,850.00. Following the completion of the sale, the executive vice president now owns 27,198 shares of the company’s stock, valued at approximately $1,869,862.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total transaction of $468,504.00. Following the completion of the sale, the executive vice president now directly owns 34,398 shares of the company’s stock, valued at approximately $2,238,277.86. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Everence Capital Management Inc. boosted its holdings in shares of Gilead Sciences by 13.7% in the 2nd quarter. Everence Capital Management Inc. now owns 26,970 shares of the biopharmaceutical company’s stock valued at $1,822,000 after buying an additional 3,240 shares during the period. Hillsdale Investment Management Inc. boosted its holdings in shares of Gilead Sciences by 13.5% in the 2nd quarter. Hillsdale Investment Management Inc. now owns 7,570 shares of the biopharmaceutical company’s stock valued at $512,000 after buying an additional 900 shares during the period. John G Ullman & Associates Inc. boosted its holdings in shares of Gilead Sciences by 78.0% in the 2nd quarter. John G Ullman & Associates Inc. now owns 5,695 shares of the biopharmaceutical company’s stock valued at $385,000 after buying an additional 2,495 shares during the period. Clarius Group LLC boosted its stake in Gilead Sciences by 24.0% during the 2nd quarter. Clarius Group LLC now owns 6,370 shares of the biopharmaceutical company’s stock valued at $430,000 after purchasing an additional 1,234 shares during the period. Finally, Landmark Bank boosted its stake in Gilead Sciences by 1.5% during the 2nd quarter. Landmark Bank now owns 47,483 shares of the biopharmaceutical company’s stock valued at $3,208,000 after purchasing an additional 693 shares during the period. 78.85% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: What is the float in trading stocks?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.